Alembic Pharmaceuticals has officially announced the appointment of Mr. Chirayu Amin as the Executive Chairman of the company, effective April 1, 2026. Following his five-year appointment, Mr. Amin has transitioned from his previous role as Chairman and CEO. This strategic leadership change comes as the company continues its focus on sustained growth and long-term organizational success under his continued guidance and leadership.
Leadership Transition
Following approval from shareholders at the 15th Annual General Meeting held on August 5, 2025, Mr. Chirayu Amin has assumed the role of Executive Chairman of Alembic Pharmaceuticals. This appointment is for a tenure of five years, effective from April 1, 2026. As part of this transition, Mr. Amin has stepped down from his former dual role as Chairman and CEO, which concluded on March 31, 2026.
Background and Strategic Role
Mr. Chirayu Amin brings extensive experience to his new position. He holds a bachelor’s degree in science from Maharaja Sayajirao University of Baroda and a master’s degree in business administration from Seton Hall University, USA. His leadership has been instrumental in the company’s history, steering it toward sustained growth and innovation. Beyond his corporate contributions, he is actively involved in philanthropic efforts, serving as a trustee for several healthcare and educational institutions.
Family Representation
The company also noted that Mr. Chirayu Amin is the father of Mr. Pranav Amin and Mr. Shaunak Amin, both of whom serve as Managing Directors of Alembic Pharmaceuticals. This leadership structure ensures a continuity of vision as the company moves into its next phase of development.
Source: BSE
